Effect of prior treatment with antipsychotic long-acting injection on randomised clinical trial treatment outcomes

British Journal of Psychiatry

Volumn 203, Issue 3, 2013, Pages 215-220

  Barnes, Thomas R E ^a,b   Drake, Richard J ^c   Dunn, Graham ^c   Hayhurst, Karen P ^c   Jones, Peter B ^d   Lewis, Shôn W ^e  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b WEST LONDON MENTAL HEALTH NHS TRUST   (United Kingdom)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^e UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; BENPERIDOL; CHLORPROMAZINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLOZAPINE; DROPERIDOL; FIRST GENERATION ANTIPSYCHOTIC AGENT; FLUPENTIXOL; FLUPENTIXOL DECANOATE; FLUPHENAZINE; FLUPHENAZINE DECANOATE; HALOPERIDOL; HALOPERIDOL DECANOATE; LOXAPINE; NEUROLEPTIC AGENT; OLANZAPINE; PIMOZIDE; PIPOTIAZINE PALMITATE; PROCHLORPERAZINE; QUETIAPINE; RISPERIDONE; SECOND GENERATION ANTIPSYCHOTIC AGENT; SERTINDOLE; SULPIRIDE; THIORIDAZINE; TRIFLUOPERAZINE; UNCLASSIFIED DRUG; ZUCLOPENTHIXOL; ZUCLOPENTHIXOL DECANOATE;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG MEGADOSE; FEMALE; FOLLOW UP; HUMAN; INJECTION; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADULT; ANTIPSYCHOTIC AGENTS; DRUG SUBSTITUTION; FEMALE; HUMANS; INJECTIONS, INTRAMUSCULAR; MALE; MEDICATION ADHERENCE; PRAGMATIC CLINICAL TRIALS AS TOPIC; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETREATMENT; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 84883482534     PISSN: 00071250     EISSN: 14721465     Source Type: Journal    
DOI: 10.1192/bjp.bp.113.125807     Document Type: Article

References (34)

1. Novick D, Haro JM, Suarez D, Perez V, Dittmann RW, Haddad PM. Predictors and clinical consequences of non-adherence with antipsychotic medication in the outpatient treatment of schizophrenia. Psychiatry Res 2010; 176: 109-13.
2. Barnes TRE, Curson DA. Long term depot antipsychotics: a risk-benefit assessment. Drug Saf 1994; 10: 464-79. (Pubitemid 24191869)
3. Barnes TRE, Shingleton-Smith A, Paton C. Antipsychotic long-acting injections: prescribing practice in the UK. Br J Psychiatry 2009; 195 (suppl): s37-42.
4. David AS, Adams C. Depot antipsychotic medication in the treatment of patients with schizophrenia: (1) meta-review; (2) patient and nurse attitudes. Health Technol Assess 2001; 5: 1-79.
5. Patel MX, David AS. Why aren't depot antipsychotics prescribed more often and what can be done about it? Adv Psychiatr Treat 2005; 11: 203-11.
6. Patel MX, Haddad PM, Chaudhry IB, McLoughlin S, Husain N, David AS. Psychiatrists' use, knowledge and attitudes to first- and second-generation antipsychotic long-acting injections: comparisons over 5 years. J Psychopharmacol 2010; 24: 1473-82.
7. National Institute for Health and Clinical Excellence. Schizophrenia: Core Interventions in the Treatment and Management of Schizophrenia in Adults in Primary and Secondary Care (Update), CG82. NICE, 2009.
8. Barnes TRE. Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2011; 25: 567-620.
9. Adams CE, Fenton MKP, Quraishi S, David AS. Systematic meta-review of depot antipsychotic drugs for people with schizophrenia. Br J Psychiatry 2001; 179: 290-9. (Pubitemid 32996037)
10. Haddad PM, Taylor M, Niaz OS. First-generation antipsychotic long-acting injections v. oral antipsychotics in schizophrenia: systematic review of randomised controlled trials and observational studies. Br J Psychiatry 2009; 195: s20-8.
11. Leucht C, Heres S, Kane JM, Kissling W, Davis JM, Leucht S. Oral versus depot antipsychotic drugs for schizophrenia - a critical systematic review and meta-analysis of randomised long-term trials. Schizophr Res 2011; 127: 83-92.
12. Rosenheck RA, Krystal JH, Lew R, Barnett PG, Fiore L, Valley D, et al. Long-acting risperidone and oral antipsychotics in unstable schizophrenia. N Engl J Med 2011; 364: 842-51.
13. Leucht S, Tardy M, Komossa K, Heres S, Kissling W, Salanti G, et al. Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. Lancet 2012; 379: 2063-71.
14. Kishimoto T, Robenzadeh A, Leucht C, Leucht S, Watanabe K, Mimura M, et al. Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials. Schizophr Bull 2013; Jan 2 (Epub ahead of print).
15. Zhu B, Ascher-Svanum H, Shi L, Faries D, Montgomery W, Marder SR. Time to discontinuation of depot and oral first-generation antipsychotics in the usual care of schizophrenia. Psychiatr Serv 2008; 59: 315-7.
16. Tiihonen J, Haukka J, Taylor M, Haddad PM, Patel MX, Korhonen P. A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. Am J Psychiatry 2011; 168: 603-9.
17. Grimaldi-Bensouda L, Rouillon F, Astruc B, Rossignol M, Benichou J, Falissard B, et al. Does long-acting injectable risperidone make a difference to the real-life treatment of schizophrenia? Results of the Cohort for the General study of Schizophrenia (CGS). Schizophr Res 2012; 134: 187-94.
18. Bitter I, Katona L, Zámbori J, Takács P, Fehér L, Diels J, et al. Comparative effectiveness of depot and oral second generation antipsychotic drugs in schizophrenia: a nationwide study in Hungary. Eur Neuropsychopharmacol 2013; Mar 7 (Epub ahead of print).
19. Lambert T, Olivares JM, Peuskens J, Desouza C, Kozma CM, Otten P, et al. Effectiveness of injectable risperidone long-acting therapy for schizophrenia: data from the US, Spain, Australia, and Belgium. Ann Gen Psychiatry 2011; 10: 10.
20. Peng X, Ascher-Svanum H, Faries D, Conley RR, Schuh KJ. Decline in hospitalization risk and health care cost after initiation of depot antipsychotics in the treatment of schizophrenia. Clinicoecon Outcomes Res 2011; 3: 9-14.
21. Bowen J, Barnes TRE. The clinical characteristics of schizophrenic patients consenting and not consenting to a placebo-controlled trial. Hum Psychopharmacol 1994; 9: 423-33.
22. Jones PB, Barnes TRE, Davies L, Dunn G, Lloyd H, Hayhurst KP, et al. Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia. Arch Gen Psychiatry 2006; 63: 1079-87.
23. Lewis SW, Barnes TRE, Davies L, Murray RM, Dunn G, Hayhurst KP, et al. Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia. Schizophr Bull 2006; 32: 715-23. (Pubitemid 44412859)
24. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (4th edn) (DSM-IV). APA, 1994.
25. Heinrichs DW, Hanlon TE, Carpenter WT. The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome. Schizophr Bull 1984; 10: 388-98.
26. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13: 261-76. (Pubitemid 18039085)
27. Addington D, Addington J, Schissel B. A depression rating scale for schizophrenics. Schizophr Res 1990; 3: 247-51. (Pubitemid 20228720)
28. Hogan TP, Awad AG, Eastwood R. A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity. Psychol Med 1983; 13: 177-83. (Pubitemid 13132147)
29. Hayward P, Chan N, Kemp R, Youle S, David A. Medication self-management: a preliminary report on an intervention to improve medication compliance. J Ment Health 1995; 4: 511-7. (Pubitemid 26009202)
30. Yusufi B, Mukherjee S, Flanagan R, Paton C, Dunn G, Page E, et al. Prevalence and nature of side effects during clozapine maintenance treatment and the relationship with clozapine dose and plasma concentration. Int Clin Psychopharmacol 2007; 22: 238-43. (Pubitemid 46801948)
31. Ohlsen RI, Williamson R, Yusufi B, Mullan J, Irving D, Mukherjee S, et al. Interrater reliability of the Antipsychotic Non-Neurological Side-Effects Rating Scale measured in patients treated with clozapine. J Psychopharmacol 2008; 22: 323-9. (Pubitemid 351847438)
32. Simpson G, Angus J. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand 1970; 45: 11-9.
33. Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry 1989; 154: 672-6. (Pubitemid 19154942)
34. Guy W. ECDEU Assessment Manual for Psychopharmacology. Revised DHEW Pub. (ADM). National Institute for Mental Health, 1976.